
## Anja Mottok

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8677005/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncology, The, 2015, 16, 1111-1122.	5.1	483
2	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 190-201.	0.8	257
3	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Medicine, 2016, 13, e1002197.	3.9	185
4	Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. Journal of Experimental Medicine, 2016, 213, 1881-1900.	4.2	143
5	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact. Blood, 2017, 129, 2760-2770.	0.6	112
6	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discovery, 2020, 10, 440-459.	7.7	103
7	Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1125-1130.	3.3	49
8	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nature Medicine, 2020, 26, 577-588.	15.2	46
9	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Blood, 2018, 131, 226-235.	0.6	31
10	Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD. Blood, 2015, 126, 437-444.	0.6	29
11	Validation of the <scp>MCL</scp> 35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. British Journal of Haematology, 2019, 184, 616-624.	1.2	25
12	The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology, 2019, 94, 1208-1213.	2.0	25
13	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood, 2021, 137, 2196-2208.	0.6	18
14	Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity. Journal of Experimental Medicine, 2021, 218, .	4.2	15
15	Convergence of risk prediction models in follicular lymphoma. Haematologica, 2019, 104, e252-e255.	1.7	9
16	Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Annals of Hematology, 2021, 100, 1537-1546.	0.8	7
17	Non-Invasive Bioluminescence Imaging to Monitor the Immunological Control of a Plasmablastic Lymphoma-Like B Cell Neoplasia after Hematopoietic Cell Transplantation. PLoS ONE, 2013, 8, e81320.	1.1	6
18	A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease. Frontiers in Immunology, 2020, 11, 593321.	2.2	4

Ανја Μοττοκ

#	Article	IF	CITATIONS
19	Methotrexate-induced lymphoproliferative disorders: regression matters. Leukemia and Lymphoma, 2018, 59, 1027-1029.	0.6	1
20	Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival Blood, 2018, 132, 3217-3217.	0.6	0
21	Tissue Derived Non-Classical Monocyte Derived Host Macrophages Protect Against Murine Intestinal Acute Graft-Versus-Host Disease. Blood, 2018, 132, 3315-3315.	0.6	0